21:45 , Oct 12, 2018 |  BioCentury  |  Finance

Versant seizes the RNA moment

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics. Versant co-led Gotham’s $54 million series...
13:56 , Sep 20, 2018 |  BC Extra  |  Preclinical News

RNA-modifying enzyme loops mRNA to increase oncogene translation

Boston Children's Hospital researchers showed interaction between a translation factor and RNA-modifying enzyme could enhance oncogene translation by circularizing mRNA, suggesting that disrupting the protein-protein interaction could help treat cancer. At least two companies --...
19:08 , May 18, 2018 |  BC Week In Review  |  Financial News

RNA epigenetics company Accent raises $40M series A

RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital. Accent’s preclinical assets are designed to treat...
09:12 , May 18, 2018 |  BC Extra  |  Financial News

Accent targeting RNA-modifying proteins with $40M series A

RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital. Accent’s preclinical assets are designed to treat...
09:09 , May 18, 2018 |  BioCentury  |  Emerging Company Profile

Accent on RNA

With its debut Friday with a $40 million series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive...